Restores Pancreas Function: Decreasing fat in the pancreas allows the beta cells (which produce insulin) to recover their function and start secreting insulin effectively again
Do not wipe them dry
GLP-1 Drugs Use, Risks, and Regulation Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar
This ensures consistency across different tests and aligns with the natural daily fluctuations of your hormones
Of those, 1,482 (37%) who initiated injectable semaglutide between March 2018 and November 2023 met all inclusion criteria: At least 2 semaglutide prescriptions 3 months apart (to be reasonably confident of ongoing use) No other GLP-1 receptor agonist within 6 months before semaglutide initiation or within the first 3 months of semaglutide use No prescription for oral semaglutide (Rybelsus) Baseline BMI 27 kg/m2, based on the most recent BMI measurement available within 6 months before (or on) the semaglutide start date At least 1 follow-up BMI measurement available 3-12 months after the semaglutide start date Among all weight measurements within up to 12 months after semaglutide initiation, BMI was calculated as weight in kilograms divided by the square of height in meters
Managing multiple prescriptions can feel overwhelming, but with the right strategies, you can minimize risks and maintain your health